NCT02593045已完成1 期
Open Label, Multicenter Phase I Study of IPH4102, a Humanized Anti-KIR3DL2 Monoclonal Antibody, in Patients With Relapsed/Refractory Cutaneous T-cell Lymphomas (CTCL)
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 44
- 试验地点
- 6
- 主要终点
- Occurrence of Dose Limiting Toxicities (DLT)
研究概览
简要总结
The primary objective of this first in human study is to assess the safety and tolerability of increasing intravenous (IV) doses of single agent IPH4102 administered to patients with relapsed/refractory CTCL to characterize the dose limiting toxicities (DLT) and identify a Maximum Tolerated Dose (MTD).
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with relapsed/refractory, biopsy-proven primary cutaneous T-cell lymphoma who have received at least two previous standard systemic therapies and, if MF/SS, is stage IB IVB at study entry.
- •Centrally assessed KIR3DL2 expression on tumor cells.
- •Patients must have the following minimum wash-out from previous treatments:
- •≥12 weeks for total skin electron beam irradiation,
- •≥4 weeks for monoclonal antibodies (≥8 weeks for alemtuzumab),
- •≥3 weeks for local radiation therapy, systemic cytotoxic anticancer therapy, treatment with other anti-neoplastic investigational agents
- •≥3 weeks for systemic retinoids, interferons, vorinostat, romidepsin, fusion proteins
- •≥3 weeks for phototherapy
- •≥2 weeks for topical therapy (including steroids, retinoids, nitrogen mustard or imiquimod) Topical steroids (maximum strength: medium potency) and oral steroids (≤10 mg prednisone equivalent/day) are allowed, if the patient has been on a stable dose with stable symptoms for at least 4 weeks prior to study entry.
- •At least 18 years of age.
- •ECOG performance status of ≤
- •Adequate baseline laboratory data: hemoglobin >9 g/dL, absolute neutrophil count (ANC) ≥1,000/µL, CD4+ T-cells ≥200/µL, platelets ≥50,000/µL, bilirubin ≤1.5 X upper limit of normal (ULN) or ≤3 X ULN for patients with Gilbert's disease, serum creatinine ≤1.5 X ULN, alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≤3 X ULN.
- •Women of childbearing potential (WOCBP) must have a negative serum beta-HCG pregnancy test result within seven days of treatment and must practice an effective method of contraception during treatment and for at least 9 months (270 days) following the last dose of study drug.
- •Female patients who are post-menopausal or surgically sterile.
- •Male patients who agree to practice effective barrier contraception.
- •Ability to understand and the willingness to sign a written informed consent document.
- •No psychological, familial, sociological, or geographical condition potentially hampering compliance with the study protocol and follow-up schedule.
排除标准
- •Patients with limited disease (if MF/SS: stages IA) or central nervous system (CNS) disease.
- •Clinical relevant AEs or laboratory results related to previous anti-neoplastic therapy have not resolved to a NCI-CTCAE grade ≤
- •Concomitant corticosteroid use, systemic or topical, for treatment of skin disease. However, topical steroids (maximum strength: medium potency) and oral steroids (≤10 mg prednisone equivalent/day) are allowed, if patient has been on a stable dose with stable symptoms for at least 4 weeks prior to study entry.
- •Patients who have undergone major surgery <4 weeks prior to starting study drug.
- •Patients who have undergone a stem cell transplantation.
- •Patients with known NCI CTCAE Grade 3 or higher (requiring IV antibiotics) active systemic or cutaneous viral, bacterial, or fungal infection.
- •Patients who are Hepatitis B or Hepatitis C antibody positive.
- •Patients who are known to be HIV-positive.
- •Prior hypersensitivity reaction to monoclonal antibodies, other therapeutic proteins, or immunotherapy.
- •Patients with a history of other malignancies during the past three years. (The following are exempt from the three-year limit: non-melanoma skin cancer, Lymphomatoid papulosis, curatively treated localized prostate cancer, curatively treated localized breast cancer, resected thyroid cancer, biopsy proven cervical intraepithelial neoplasia or cervical carcinoma in situ).
- •Patients who are currently pregnant or breastfeeding.
- •Patients with congestive heart failure, Class III or IV, by New York Heart Association (NYHA) criteria.
- •Patients with any serious underlying medical condition that would impair their ability to receive or tolerate the planned treatment.
- •Patients with dementia or altered mental status that would preclude understanding and rendering of informed consent document.
结局指标
主要结局
Occurrence of Dose Limiting Toxicities (DLT)
时间窗: Within 2 weeks after the first administration
次要结局
未报告次要终点
研究者
研究点 (6)
Loading locations...
相似试验
已完成
1 期
A First-in-human Single and Repeated Dose Escalation Study of SAR442501 in Healthy Adults SubjectsOsteochondrodysplasiaNCT05846009Sanofi76
终止
1 期
Dose Finding Study of TNO155 in Adult Patients With Advanced Solid TumorsNCT03114319Novartis Pharmaceuticals227
进行中（未招募）
1 期
First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid TumorsNeoplasmsNCT05277051GlaxoSmithKline152
终止
1 期
A Phase 1/2a, Single- and Multiple-dose Escalation Study of KRRO-110Alpha-1 Anti-trypsin DeficiencyAATDNCT06677307Korro Bio, Inc.42
终止
1 期
A Study of AZD0466 in Patients With Advanced Hematologic or Solid TumorsAdvanced Solid TumorsHematologic MalignanciesMultiple MyelomaLymphomaNCT04214093AstraZeneca9